Kevin Molloy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin Molloy has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Ahmed Aljorfi
Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Education & Research Centre, Beaumont Hospital, Dublin 9, Ireland
1 shared publication- Anne-Marie Tobin
Department of Dermatology, Tallaght University Hospital , Tallaght, Dublin
1 shared publication - Catherine M. Greene
RCSI University of Medicine and Health Sciences
1 shared publication Charles Pilette
Institute of Experimental and Clinical Research, Pole of Pneumology, ENT and Dermatology, Université Catholique de Louvain (UCL), Brussels, Belgium
1 shared publicationDavid A. Bergin
Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Education & Research Centre, Beaumont Hospital, Dublin 9, Ireland
1 shared publicationDorothy M. Ryan
Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Education & Research Centre, Beaumont Hospital, Dublin 9, Ireland
1 shared publication
Latest Publications
- Open Access
- 8 April 2018
- Published by Wiley in Mediators of Inflammation
- Vol. 2018, 1-20
Airway Epithelium Dysfunction in Cystic Fibrosis and COPD
Cystic fibrosis is a genetic disease caused by mutations in the CFTR gene, whereas chronic obstructive pulmonary disease (COPD) is mainly caused by environmental factors (mostly cigarette smoking) on a genetically susceptible background. Although the etiology and pathogenesis of these diseases are different, both are associated with progressive airflow obstruction, airway neutrophilic inflammation, and recurrent exacerbations, suggesting common mechanisms. The airway epithelium plays a crucial role in maintaining normal airway functions. Major molecular and morphologic changes occur in the airway epithelium in both CF and COPD, and growing evidence suggests that airway epithelial dysfunction is involved in disease initiation and progression in both diseases. Structural and functional abnormalities in both airway and alveolar epithelium have a relevant impact on alteration of host defences, immune/inflammatory response, and the repair process leading to progressive lung damage and impaired lung function. In this review, we address the evidence for a critical role of dysfunctional airway epithelial cells in chronic airway inflammation and remodelling in CF and COPD, highlighting the common mechanisms involved in the epithelial dysfunction as well as the similarities and differences of the two diseases.
- 8 April 2018
- Published by Wiley in Mediators of Inflammation
- Vol. 2018, 1-20
Open AccessAirway Epithelium Dysfunction in Cystic Fibrosis and COPD
Cystic fibrosis is a genetic disease caused by mutations in the CFTR gene, whereas chronic obstructive pulmonary disease (COPD) is mainly caused by environmental factors (mostly cigarette smoking) on a genetically susceptible background. Although the etiology and pathogenesis of these diseases are different, both are associated with progressive airflow obstruction, airway neutrophilic inflammation, and recurrent exacerbations, suggesting common mechanisms. The airway epithelium plays a crucial role in maintaining normal airway functions. Major molecular and morphologic changes occur in the airway epithelium in both CF and COPD, and growing evidence suggests that airway epithelial dysfunction is involved in disease initiation and progression in both diseases. Structural and functional abnormalities in both airway and alveolar epithelium have a relevant impact on alteration of host defences, immune/inflammatory response, and the repair process leading to progressive lung damage and impaired lung function. In this review, we address the evidence for a critical role of dysfunctional airway epithelial cells in chronic airway inflammation and remodelling in CF and COPD, highlighting the common mechanisms involved in the epithelial dysfunction as well as the similarities and differences of the two diseases.
- 27 November 2017
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 34 (3) , 217-219
Narrow‐band ultraviolet B phototherapy outcomes in atopic dermatitis—A single‐centre retrospective review
- 27 November 2017
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 34 (3) , 217-219
Narrow‐band ultraviolet B phototherapy outcomes in atopic dermatitis—A single‐centre retrospective review
- Open Access
- 1 January 2013
- Published by Wiley in BioMed Research International
- Vol. 2013, 1-18
Intracellular Secretory Leukoprotease Inhibitor Modulates Inositol 1,4,5-Triphosphate Generation and Exerts an Anti-Inflammatory Effect on Neutrophils of Individuals with Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
Secretory leukoprotease inhibitor (SLPI) is an anti-inflammatory protein present in respiratory secretions. Whilst epithelial cell SLPI is extensively studied, neutrophil associated SLPI is poorly characterised. Neutrophil function including chemotaxis and degranulation of proteolytic enzymes involves changes in cytosolic calcium (Ca2+) levels which is mediated by production of inositol 1,4,5-triphosphate (IP3) in response to G-protein-coupled receptor (GPCR) stimuli. The aim of this study was to investigate the intracellular function of SLPI and the mechanism-based modulation of neutrophil function by this antiprotease. Neutrophils were isolated from healthy controls (), individuals with cystic fibrosis (CF) () or chronic obstructive pulmonary disease (COPD) (). Recombinant human SLPI significantly inhibited fMet-Leu-Phe (fMLP) and interleukin(IL)-8 induced neutrophil chemotaxis () and decreased degranulation of matrix metalloprotease-9 (MMP-9), hCAP-18, and myeloperoxidase (MPO) (). The mechanism of inhibition involved modulation of cytosolic IP3production and downstream Ca2+flux. The described attenuation of Ca2+flux was overcome by inclusion of exogenous IP3in electropermeabilized cells. Inhibition of IP3generation and Ca2+flux by SLPI may represent a novel anti-inflammatory mechanism, thus strengthening the attractiveness of SLPI as a potential therapeutic molecule in inflammatory airway disease associated with excessive neutrophil influx including CF, non-CF bronchiectasis, and COPD.- 1 January 2013
- Published by Wiley in BioMed Research International
- Vol. 2013, 1-18
Open AccessIntracellular Secretory Leukoprotease Inhibitor Modulates Inositol 1,4,5-Triphosphate Generation and Exerts an Anti-Inflammatory Effect on Neutrophils of Individuals with Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
Secretory leukoprotease inhibitor (SLPI) is an anti-inflammatory protein present in respiratory secretions. Whilst epithelial cell SLPI is extensively studied, neutrophil associated SLPI is poorly characterised. Neutrophil function including chemotaxis and degranulation of proteolytic enzymes involves changes in cytosolic calcium (Ca2+) levels which is mediated by production of inositol 1,4,5-triphosphate (IP3) in response to G-protein-coupled receptor (GPCR) stimuli. The aim of this study was to investigate the intracellular function of SLPI and the mechanism-based modulation of neutrophil function by this antiprotease. Neutrophils were isolated from healthy controls (), individuals with cystic fibrosis (CF) () or chronic obstructive pulmonary disease (COPD) (). Recombinant human SLPI significantly inhibited fMet-Leu-Phe (fMLP) and interleukin(IL)-8 induced neutrophil chemotaxis () and decreased degranulation of matrix metalloprotease-9 (MMP-9), hCAP-18, and myeloperoxidase (MPO) (). The mechanism of inhibition involved modulation of cytosolic IP3production and downstream Ca2+flux. The described attenuation of Ca2+flux was overcome by inclusion of exogenous IP3in electropermeabilized cells. Inhibition of IP3generation and Ca2+flux by SLPI may represent a novel anti-inflammatory mechanism, thus strengthening the attractiveness of SLPI as a potential therapeutic molecule in inflammatory airway disease associated with excessive neutrophil influx including CF, non-CF bronchiectasis, and COPD.